Figure 2. Affinity-enhanced A97L-TCR-T cells significantly improve tumor control and survival.

(A) Schematic of ACT study. (B) Control of A375 tumors (left) in NSG mice and survival curves (right) following ACT (n = 6 mice per group; data are representative of 2 independent studies). (C) Number of intratumoral human CD8⁺ (left) and CD4⁺ (right) T cells per milligram of tumor 7 days after ACT (n = 5; data are representative of 2 independent studies). (D) Ratio of intratumoral CD8⁺/CD4⁺ human T cell frequency 7 days after ACT (n = 5; data are representative of 2 independent studies). (E) Frequency (left) and geometric mean fluorescence intensity (G-MFI) (right) of Ki-67 expression within intratumoral human CD8⁺ T cells 7 days after ACT (n ≥4; data are representative of 2 independent studies). (F) Number of intratumoral mouse F4-80^hi macrophages per milligram of tumor 7 days after ACT (n = 5; data are representative of 2 independent studies). (G) G-MFI of mouse SiRPα expression within intratumoral mouse F4-80^hi macrophages 7 days after ACT (n = 5; data are representative of 2 independent studies). Statistical analysis was done by 2-way ANOVA (B, left), Mantel-Cox (B, right), or 1-way ANOVA (C–G) with correction for multiple comparisons by post hoc Tukey’s test (B–G). *P < 0.05; **P < 0.01; ***P < 0.001; ****P< 0.0001.